Idiopathic pulmonary fibrosis (IPF) is a chronic progressive fibrotic interstitial pneumonia
with unknown causes. The incidence rate increases year by year and the prognosis is poor …

Lung, breast, and esophageal cancer represent three common malignancies with high
incidence and mortality worldwide. The management of these tumors critically relies on …

Background As COVID-19 cases continue to rise globally, evidence from large randomized
controlled trials is still lacking. Currently, numerous trials testing potential treatment and …

Rationale: Idiopathic pulmonary fibrosis (IPF) is a chronic, progressive, and often fatal
disorder. Two US Food and Drug Administration–approved antifibrotic drugs, nintedanib and …

Background Pirfenidone (PFD) is effective for pulmonary fibrosis (PF), but its action
mechanism has not been fully explained. This study explored the signaling pathways …

Development of organoids and microfluidic on-chip models has enabled studies of organ-
level disease pathophysiologies in vitro. However, current lung-on-a-chip platforms are …

Idiopathic pulmonary fibrosis (IPF) is a chronic, progressive disease with high mortality that
commonly occurs in middle-aged and older adults. IPF, characterized by a decline in lung …

Diabetic kidney disease (DKD) is not only one of the main complications of diabetes, but
also the leading cause of the end-stage renal disease (ESRD). The occurrence and …

Myofibroblasts are the major cellular source of collagen, and their accumulation—via
differentiation from fibroblasts and resistance to apoptosis—is a hallmark of tissue fibrosis …

Pirfenidone (PFD) is a non-peptide synthetic chemical that inhibits the production of
transforming growth factor-beta 1 (TGF-β1), tumor necrosis factor-alpha (TNF-α), platelet …